Geistlich Derma-Gide® Added to the General Services Administration’s Federal Supply Schedule

Oct. 16, 2020 13:00 UTC

Geistlich Derma-Gide® Added to the General Services Administration’s Federal Supply Schedule


PRINCETON, N.J.--(BUSINESS WIRE)-- The Geistlich Medical business unit of Geistlich Pharma AG, a family owned, Swiss based global leader in regenerative solutions is proud to announce that the General Services Administration (GSA) has added Geistlich Derma-Gide® Advanced Wound Matrix to the Federal Supply Schedule (FSS). Geistlich Pharma focuses on a wide variety of clinical indications.

The GSA award will pave the way for physicians and staff of Veterans Administration facilities to utilize Geistlich Derma-Gide® for the management of hard to heal wounds. The product is FDA cleared for a wide variety of indications, including diabetic foot ulcers, venous leg ulcers, surgical wounds, and first/second degree burns (among others).

Advanced wound care for those in need

Geistlich Medical has partnered with Recon-Supply, a Service-Disabled Veteran-Owned Small Business owned by Marine Corps veteran Stephen Clark and his wife Katy Clark. “It was important to Geistlich Medical to partner with a SDVOSB in order to support and honor those that have served in the US Military,” says Geistlich CEO Paul Note. “We found a great organization in Recon-Supply and look forward to serving the Veterans Administration facilities as they treat those in need of advanced wound care.” All nine of the Geistlich Derma-Gide® sizes are a part of the FSS so that physicians and their staff have full access to the portfolio of products available to the broader healthcare market.

Novel second-generation xenograft

Geistlich Derma-Gide® Advanced Wound Matrix is a novel second generation xenograft product that features an advanced 4D design: Dual-sourced, highly refined, bi-layered, and structurally optimized. It has demonstrated a 90% closure rate in its first 10 patient observational study recently published in International Wound Journal1. A larger prospective, randomized clinical trial is currently underway, with interim results to be published in late 2020.

1 Armstrong, DG, Orgill, DP, Galiano, RD, et al. An observational pilot study using a purified reconstituted bilayer matrix to treat non‐healing diabetic foot ulcers. Int Wound J. 2020; 17: 966– 973.

About Geistlich Pharma

Geistlich Pharma has existed since 1851 and is family-owned. It specializes in the regeneration of bone, cartilage and tissue. More than 700 employees worldwide work for Geistlich in the area of regenerative medicine. With its twelve affiliates and 60 distribution partners, Geistlich’s medical devices and medicinal products reach around 90 markets worldwide.


Christie Blakely
Questions, inquiries: 877-485-2968


Source: Geistlich Pharma

Back to news